Immunophotonics, Inc.

📍 St. Louis, United States🗓 Founded 2012👥 17 employees💰 Last funded Sep 2021
Pharmaceutical Manufacturing🌐 immunophotonics.com
Website LinkedIn
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Immunophotonics, Inc.?
Immunophotonics, Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did Immunophotonics, Inc. last raise funding?
The most recent investment in Immunophotonics, Inc. recorded on gritt.io was in September 2021.
When was Immunophotonics, Inc. founded?
Immunophotonics, Inc. was founded in 2012.
What industry is Immunophotonics, Inc. in?
Immunophotonics, Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Immunophotonics, Inc. based?
Immunophotonics, Inc. is headquartered in St. Louis, United States.